Skip to main content
Top
Published in: Endocrine 3/2012

01-06-2012 | Original Article

Positive correlation between type 1 and 2 iodothyronine deiodinases activities in human goiters

Authors: Valmara S. Pereira, Michelle P. Marassi, Doris Rosenthal, Mário Vaisman, Vânia M. Corrêa da Costa

Published in: Endocrine | Issue 3/2012

Login to get access

Abstract

Type 1 (D1) and 2 (D2) iodothyronine deiodinases are selenocysteine-containing enzymes that catalyze the deiodination of T4 to T3 in the thyroid and in peripheral tissues. Despite their importance to the plasma T3 pool in human beings, there are few studies about their behavior in human thyroids. In order to better understand iodothyronine deiodinase regulation in the thyroid gland, we studied thyroid tissue samples from follicular adenoma (AD, n = 5), toxic diffuse goiter (TDG, n = 6), nontoxic multinodular goiter (NMG, n = 40), papillary thyroid carcinoma (PTC, n = 8), and surrounding normal tissues (NT, n = 7) from 36 patients submitted to elective thyroidectomy. D1 and D2 activities were determined by quantification of the radioiodine released by 125I-rT3 or 125I-T4 under standardized conditions, and expressed as pmol rT3 deiodinated per minute and mg protein (pmol rT3 min−1 mg−1 ptn) and fmol T4 deiodinated per minute and mg protein (fmol T4 min−1 mg−1 ptn), respectively. D1 activity detected in TDG and AD tissues were significantly higher than in NT, PTC or NMG samples. D2 activity was also significantly higher in TDG and AD samples than in PTC, NMG, or NT. There was great variability in D1 and D2 enzymatic activities from distinct patients as well as from different areas from the same goiter. There was a positive correlation (P < 0,0001, r = 0.4942) between D1 and D2 activities when all samples were taken into account, suggesting that—in the thyroid—these two iodothyronine deiodinases may have related regulatory mechanisms, even if conditioned by other as yet unknown factors.
Appendix
Available only for authorised users
Literature
1.
go back to reference D.L. St Germain, V.A. Galton, A. Hernandez, Minireview: definig the roles of the iodothyronine deiodinases: current concepts and challenges. Endocrinology 150, 1097–1107 (2009)PubMedCrossRef D.L. St Germain, V.A. Galton, A. Hernandez, Minireview: definig the roles of the iodothyronine deiodinases: current concepts and challenges. Endocrinology 150, 1097–1107 (2009)PubMedCrossRef
2.
go back to reference M. Murakami, O. Araki, Y. Hosoi, Y. Kamiya, T. Morimura, T. Ogiwara, H. Mizuma, M. Mori, Expression and regulation of type II iodothyronine deiodinase in human thyroid gland. Endocrinology 142, 2961–2967 (2001)PubMedCrossRef M. Murakami, O. Araki, Y. Hosoi, Y. Kamiya, T. Morimura, T. Ogiwara, H. Mizuma, M. Mori, Expression and regulation of type II iodothyronine deiodinase in human thyroid gland. Endocrinology 142, 2961–2967 (2001)PubMedCrossRef
3.
go back to reference C. Curcio, M.M.A. Baqui, D. Salvatore, B.H. Rihn, S. Mohr, J.W. Harney, P.R. Larsen, A.C. Bianco, The human type 2 iodothyronine deiodinase is a selenoprotein highly expressed in a mesothelioma cell line. J. Biol. Chem. 276, 30183–30187 (2001)PubMedCrossRef C. Curcio, M.M.A. Baqui, D. Salvatore, B.H. Rihn, S. Mohr, J.W. Harney, P.R. Larsen, A.C. Bianco, The human type 2 iodothyronine deiodinase is a selenoprotein highly expressed in a mesothelioma cell line. J. Biol. Chem. 276, 30183–30187 (2001)PubMedCrossRef
4.
go back to reference J. Köhrle, Thyroid carcinoma: interrelationships between local thyroid hormone metabolism by type 1 5′-deiodinase and expression of thyroid hormone receptors and other thyroid-specific (de-) differentiation markers. Curr. Top. Pathol. 91, 83–116 (1997)PubMedCrossRef J. Köhrle, Thyroid carcinoma: interrelationships between local thyroid hormone metabolism by type 1 5′-deiodinase and expression of thyroid hormone receptors and other thyroid-specific (de-) differentiation markers. Curr. Top. Pathol. 91, 83–116 (1997)PubMedCrossRef
5.
go back to reference C.E. Hedinger, E.D. Williams, L.H. Sobin, Histological typing of thyroid tumours, in WHO International Histological Classification of Tumours, 2nd ed. (Springer-Verlag, Berlin, 1988), pp. 5–6 C.E. Hedinger, E.D. Williams, L.H. Sobin, Histological typing of thyroid tumours, in WHO International Histological Classification of Tumours, 2nd ed. (Springer-Verlag, Berlin, 1988), pp. 5–6
6.
go back to reference F.L. Greene, L.H. Sobin, The TNM system: our language for cancer care. J. Surg. Oncol. 80, 119–120 (2002)PubMedCrossRef F.L. Greene, L.H. Sobin, The TNM system: our language for cancer care. J. Surg. Oncol. 80, 119–120 (2002)PubMedCrossRef
7.
go back to reference M.P. Marassi, R.S. Fortunato, A.C. Matos da Silva, V.S. Pereira, D.P. Carvalho, D. Rosenthal, V.M. Corrêa da Costa, Sexual dimorphism in thyroid function and type 1 iodothyronine deiodinase activity in pre-pubertal and adults rats. J. Endocrinol. 192, 121–130 (2007)PubMedCrossRef M.P. Marassi, R.S. Fortunato, A.C. Matos da Silva, V.S. Pereira, D.P. Carvalho, D. Rosenthal, V.M. Corrêa da Costa, Sexual dimorphism in thyroid function and type 1 iodothyronine deiodinase activity in pre-pubertal and adults rats. J. Endocrinol. 192, 121–130 (2007)PubMedCrossRef
8.
go back to reference T.U. Pantaleão, F. Mousovich, D. Rosenthal, D.P. Carvalho, V.M. Corrêa da Costa, Effect of serum estradiol and leptin levels on thyroid function, food intake and body weight gain in female Wistar rats. Steroids 75, 638–642 (2010)PubMedCrossRef T.U. Pantaleão, F. Mousovich, D. Rosenthal, D.P. Carvalho, V.M. Corrêa da Costa, Effect of serum estradiol and leptin levels on thyroid function, food intake and body weight gain in female Wistar rats. Steroids 75, 638–642 (2010)PubMedCrossRef
9.
go back to reference M.M. Bradford, A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 72, 248–254 (1976)PubMedCrossRef M.M. Bradford, A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 72, 248–254 (1976)PubMedCrossRef
10.
go back to reference R.J. Koenig, Regulation of type 1 iodothyronine deiodinase in health and disease. Thyroid 15, 835–840 (2005)PubMedCrossRef R.J. Koenig, Regulation of type 1 iodothyronine deiodinase in health and disease. Thyroid 15, 835–840 (2005)PubMedCrossRef
11.
go back to reference J. Pachucki, M. Ambroziak, Z. Tanski, J. Luczak, J. Nauman, Nauman A type 1 5′-iodothyronine deiodinase activity and mRNA are remarkably reduced in renal clear cell carcinoma. J. Endocrinol. Invest. 24, 253–261 (2001)PubMed J. Pachucki, M. Ambroziak, Z. Tanski, J. Luczak, J. Nauman, Nauman A type 1 5′-iodothyronine deiodinase activity and mRNA are remarkably reduced in renal clear cell carcinoma. J. Endocrinol. Invest. 24, 253–261 (2001)PubMed
12.
go back to reference P. Lauberg, H. Vestergaard, S. Nielsen, S.E. Christensen, T. Seefeldt, K. Helleberg, K.M. Pedersen, Sources of circulating 3,5,3′-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. J. Clin. Endocrinol. Metab. 92, 2149–2156 (2007)CrossRef P. Lauberg, H. Vestergaard, S. Nielsen, S.E. Christensen, T. Seefeldt, K. Helleberg, K.M. Pedersen, Sources of circulating 3,5,3′-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. J. Clin. Endocrinol. Metab. 92, 2149–2156 (2007)CrossRef
13.
go back to reference D. Salvatore, H. Tu, J.W. Harney, P.R. Larsen, Type 2 iodothyronine deiodinase is highly expressed in human thyroid. J. Clin. Invest. 98, 962–968 (1996)PubMedCrossRef D. Salvatore, H. Tu, J.W. Harney, P.R. Larsen, Type 2 iodothyronine deiodinase is highly expressed in human thyroid. J. Clin. Invest. 98, 962–968 (1996)PubMedCrossRef
Metadata
Title
Positive correlation between type 1 and 2 iodothyronine deiodinases activities in human goiters
Authors
Valmara S. Pereira
Michelle P. Marassi
Doris Rosenthal
Mário Vaisman
Vânia M. Corrêa da Costa
Publication date
01-06-2012
Publisher
Springer US
Published in
Endocrine / Issue 3/2012
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-011-9587-6

Other articles of this Issue 3/2012

Endocrine 3/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine